Literature DB >> 19278605

Update on the metabolic syndrome: hypertension.

Kristi Reynolds1, Rachel P Wildman.   

Abstract

The presence of the metabolic syndrome identifies an individual at increased risk for diabetes, cardiovascular disease, and early mortality. However, the increased risk may vary by the absence or presence of hypertension. Current guidelines for the management of high blood pressure in the metabolic syndrome emphasize lifestyle modification as a first-line strategy. Pharmacologic treatment of elevated blood pressure in the metabolic syndrome may be necessary in the presence of other cardiovascular risk factors or to achieve adequate blood pressure control. Currently, there is no consensus as to which antihypertensive therapy should be used to treat hypertension in patients with the metabolic syndrome; it remains unclear whether achieving tight blood pressure control should outweigh the potential for development of glucose intolerance. Future research must focus on this issue given the high prevalence of the syndrome among hypertensive patients and high rates of progression to diabetes among those with the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19278605     DOI: 10.1007/s11906-009-0026-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  48 in total

Review 1.  American College of Endocrinology position statement on the insulin resistance syndrome.

Authors:  Daniel Einhorn; Gerald M Reaven; Rhoda H Cobin; Earl Ford; Om P Ganda; Yehuda Handelsman; Richard Hellman; Paul S Jellinger; David Kendall; Ronald M Krauss; Naomi D Neufeld; Steven M Petak; Helena W Rodbard; John A Seibel; Donald A Smith; Peter W F Wilson
Journal:  Endocr Pract       Date:  2003 May-Jun       Impact factor: 3.443

Review 2.  Antihypertensive therapy and new onset diabetes.

Authors:  Franz H Messerli; Ehud Grossman; Gastone Leonetti
Journal:  J Hypertens       Date:  2004-10       Impact factor: 4.844

3.  Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.

Authors:  John B Kostis; Alan C Wilson; Ronald S Freudenberger; Nora M Cosgrove; Sara L Pressel; Barry R Davis
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

4.  Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome.

Authors:  Ettore Malacco; Stefano Omboni
Journal:  Adv Ther       Date:  2007 Sep-Oct       Impact factor: 3.845

5.  Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome.

Authors:  Leila Azadbakht; Parvin Mirmiran; Ahmad Esmaillzadeh; Tohid Azizi; Fereidoun Azizi
Journal:  Diabetes Care       Date:  2005-12       Impact factor: 19.112

6.  Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study.

Authors:  Martin K Rutter; James B Meigs; Lisa M Sullivan; Ralph B D'Agostino; Peter W Wilson
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

Review 7.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

8.  Increasing prevalence of the metabolic syndrome among u.s. Adults.

Authors:  Earl S Ford; Wayne H Giles; Ali H Mokdad
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  The metabolic syndrome: similar deleterious impact on all-cause mortality in hypertensive and normotensive subjects.

Authors:  Bruno Pannier; Frédérique Thomas; Kathy Bean; Bertrand Jégo; Athanase Benetos; Louis Guize
Journal:  J Hypertens       Date:  2008-06       Impact factor: 4.844

View more
  7 in total

1.  Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.

Authors:  Edwin K Jackson; Zaichuan Mi; Stevan P Tofovic; Delbert G Gillespie
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.

Authors:  Edwin K Jackson; Stanton J Kochanek; Delbert G Gillespie
Journal:  Hypertension       Date:  2012-07-16       Impact factor: 10.190

3.  Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.

Authors:  Francisco J Martinez-Martin; Alicia Macias-Batista; Cristina Comi-Diaz; Herminia Rodriguez-Rosas; Paula Soriano-Perera; Pablo Pedrianes-Martin
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

4.  Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly.

Authors:  Lay Gan; Shivakumar Chitturi; Geoffrey C Farrell
Journal:  Curr Gerontol Geriatr Res       Date:  2011-09-12

5.  Plasma Proteomic Signature in Overweight Girls Closely Correlates with Homeostasis Model Assessment (HOMA), an Objective Measure of Insulin Resistance.

Authors:  Stephen W Rothwell; Merrily Poth; Harkirtin McIver; Chiedozie Ayika; Ofer Eidelman; Catherine Jozwik; Harvey B Pollard
Journal:  Hum Genomics Proteomics       Date:  2011-10-06

Review 6.  The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease.

Authors:  Sylwia Ziolkowska; Agata Binienda; Maciej Jabłkowski; Janusz Szemraj; Piotr Czarny
Journal:  Int J Mol Sci       Date:  2021-10-15       Impact factor: 5.923

7.  Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population: Normal is not the new normal.

Authors:  Lin-Yan Qian; Jian-Fei Tu; Ya-Hui Ding; Jie Pang; Xian-Da Che; Hai Zou; Dong-Sheng Huang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.